Why intestinal regularity is central to the management of IBS-C and chronic constipation
Chronic constipation and irritable bowel syndrome with constipation (IBS-C) are widespread functional conditions that are often underestimated, yet capable of profoundly affecting quality of life. Difficult bowel movements, hard stools, abdominal bloating, and a sensation of incomplete evacuation accompany many patients on a daily basis, generating both physical and psychological discomfort.
In this context, restoring a more physiological intestinal regularity is not merely a symptomatic goal, but a true therapeutic cornerstone.
Constipation and IBS-C: when the problem goes beyond bowel movement frequency
In IBS-C, constipation is not simply a reduction in the number of weekly bowel movements. The issue primarily concerns the quality of evacuation: straining during defecation, stool consistency, and the perception of incomplete emptying.
These elements contribute to maintaining a vicious cycle in which the intestine becomes progressively less efficient and the patient increasingly conditioned by symptoms. For this reason, clinical guidelines suggest interventions that act in a gradual and physiological manner on intestinal function.
Clinical evidence on Macrogol 3350 in IBS-C
A randomized, double-blind, placebo-controlled study, published in the American Journal of Gastroenterology, evaluated the efficacy of PEG 3350 with electrolytes in adult patients with IBS-C.
What the study demonstrates
After 28 days of treatment, patients treated with Macrogol 3350 showed a statistically significant increase in the number of spontaneous bowel movements compared with placebo. In addition, improvements were observed in stool consistency, completeness of evacuation, and reduction of straining.
These findings confirm that Macrogol acts effectively on the constipation component of IBS-C, improving the evacuation parameters most relevant in clinical practice.
Safety and tolerability over time
From a safety perspective, the profile of Macrogol 3350 proved to be favorable. Reported adverse events were mild and comparable to placebo, confirming the product’s suitability even for long-term use, a crucial aspect in the management of chronic conditions.
Why Macrogol 3350 is a reference treatment in chronic constipation
Macrogol 3350 is an osmotic laxative with a physiological mechanism of action: it draws water into the intestinal lumen, promoting stool hydration and more natural evacuation.
Unlike other solutions, it is not absorbed by the intestine, is eliminated unchanged in the feces, does not ferment, and does not irritate the mucosa. Moreover, its efficacy does not tend to decrease over time, making it particularly suitable for the management of chronic and functional constipation.
Colestip: PJ Pharma’s answer to supporting intestinal regularity
Within the PJ Pharma gastroenterology portfolio, Colestip represents a targeted solution for the management of chronic constipation and alterations in intestinal regularity. It is a medical device based on Macrogol 3350, an osmotic laxative widely used in clinical practice for its effectiveness and safety profile.
Thanks to its physiological mechanism of action, Colestip promotes hydration of the intestinal contents, helping to soften stools and facilitate a more natural bowel movement without aggressively stimulating intestinal motility. This aspect is particularly relevant in patients with functional constipation and IBS-C, where a gentle therapeutic approach is essential.
Practical support in daily clinical practice
Colestip is formulated in sachets, a practical mode of administration that promotes treatment adherence and allows flexible management over time. The ability to tailor intake to patient needs makes Colestip suitable for both continuous treatments and medium- to long-term intestinal regularity support.
The good tolerability profile of Macrogol 3350 allows Colestip to be used even in patients requiring prolonged treatment, reducing the risk of intestinal irritation or loss of efficacy over time. This makes the product particularly suitable for daily clinical practice, where treatment continuity is often a decisive factor for therapeutic success.
Consistency with scientific evidence
Available clinical evidence on Macrogol 3350 clearly demonstrates that improving intestinal regularity is a realistic, measurable, and clinically relevant goal. Controlled studies have shown significant benefits in bowel movement frequency, stool consistency, and reduction of defecation strain.
Colestip fits into this context as a solution consistent with the scientific rationale, translating research findings into a concrete tool for the management of chronic constipation. Its use aligns with recommendations that favor gradual and physiological interventions, particularly in functional intestinal disorders.
From research to well-being: a rational approach to constipation
The management of IBS-C often requires an integrated and personalized approach, but controlling constipation represents one of the first and most important steps in improving patient well-being. Restoring more effective intestinal regularity means reducing one of the main sources of discomfort and laying the foundation for better overall symptom management.
With Colestip, PJ Pharma offers a solution based on scientific evidence and oriented toward intestinal physiology, supporting clinicians and patients in a rational, safe, and quality-of-life–focused treatment pathway.
Colestip is available as a private label or ready-to-market product. Contact us for more information
Source: Chapman RW et al. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. American Journal of Gastroenterology
